Journal Mobile Options
Table of Contents
Vol. 12, No. 3, 1974
Issue release date: 1974
Pharmacology 1974;12:166–176
(DOI:10.1159/000136535)

Neuropathology of Cyanate Toxicity in Rhesus Monkeys

Preliminary report

Shaw C.-M. · Papayannopoulou T. · Stamatoyannopoulos G.
Departments of Pathology (Neuropathology) and Medicine (Hematology and Genetics), University of Washington Medical School, Seattle, Wash.

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Clinical and neuropathological findings in 2 rhesus monkeys receiving intramuscular injections of sodium cyanate 40 mg/kg/day (5 days/week) are presented. The monkeys after 6 weeks of cyanate injections developed a spastic quadriplegia, showing no signs of recovery inspite of discontinuation of cyanate injections. Multifocal, relatively subtle microscopic abnormalities were found in both central and peripheral nervous systems. They were demyelination, capillary proliferation, glial proliferations and PAS-positive granules accumulating in the cytoplasm and processes of glial cells in the basal ganglia and colliculi, central chromatolysis of large neurons in the spinal cord, basal ganglia and cerebral cortex, and widespread myelin ‘digestion chambers’ in the peripheral nerves. This study suggests that the monkey is a proper experimental animal for the investigation of the problems of neurotoxicity raised by the use of cyanate in the treatment of patients with sickle cell anemia.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50